Your browser doesn't support javascript.
loading
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Kroschinsky, Frank; Middeke, Jan Moritz; Janz, Martin; Lenz, Georg; Witzens-Harig, Mathias; Bouabdallah, Reda; La Rosée, Paul; Viardot, Andreas; Salles, Gilles; Kim, Seok Jin; Kim, Tae Min; Ottmann, Oliver; Chromik, Joerg; Quinson, Anne-Marie; von Wangenheim, Ute; Burkard, Ute; Berk, Andreas; Schmitz, Norbert.
Afiliação
  • Kroschinsky F; Medical Department I, University Hospital at the Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
  • Middeke JM; Medical Department I, University Hospital at the Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
  • Janz M; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
  • Lenz G; Department of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  • Witzens-Harig M; Internal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany.
  • Bouabdallah R; Department ofHematology, Institute Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.
  • La Rosée P; Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany.
  • Viardot A; Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Villingen-Schweningen, Germany.
  • Salles G; Department of Internal Medicine III, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
  • Kim SJ; Department of Hematology, University Hospital of South Lyon, 165 Chemin du Grand Revoyet, 69310, Pierre-Bénite, France.
  • Kim TM; Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Irwon-dong, Gangnam-gu, Seoul, South Korea.
  • Ottmann O; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-Ro Jongno-Gu, Seoul, 03080, South Korea.
  • Chromik J; Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, South Korea.
  • Quinson AM; Division of Cancer and Genetics, Department of Haematology, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
  • von Wangenheim U; Universitätsklinikum Frankfurt, Johann-Wolfgang-Goethe-Universität, Theodor-W.-Adorno-Platz 1, 60323, Frankfurt, Germany.
  • Burkard U; Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
  • Berk A; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.
  • Schmitz N; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.
Invest New Drugs ; 39(1): 285-286, 2021 Feb.
Article em En | MEDLINE | ID: mdl-32578153
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha